A Phase 11B, Open-Label, Multicenter, First-In-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642 as a Single Agent and in Combination in Participants with Advanced Solid Tumors

2025-522148-42-00 Protocol VVD-159642-01 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 4 sites · Protocol VVD-159642-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 152
Countries 1
Sites 4

Advanced Solid Tumours

Key facts

Sponsor
Vividion Therapeutics Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2025-09-26
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-522148-42-00
ClinicalTrials.gov
NCT06804824

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumours

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Vividion Therapeutics Inc.

Sponsor organisation
Vividion Therapeutics Inc.
Address
5820 Nancy Ridge Drive
City
San Diego
Postcode
92121-2842
Country
United States

Scientific contact point

Organisation
Vividion Therapeutics Inc.
Contact name
Rajesh Belani

Public contact point

Organisation
Vividion Therapeutics Inc.
Contact name
Rajesh Belani

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Authorised, recruitment pending 32 4
Rest of world
Korea, Republic of, United States, Australia
120

Investigational sites

Spain

4 sites · Authorised, recruitment pending
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid
Hospital Hm Nou Delfos
Oncology, Avinguda De Vallcarca 151, 08023, Barcelona

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-06-30 Spain Acceptable
2025-09-22
2025-09-26